Guidance

UKHSA's Vaccine Development and Evaluation Centre (VDEC)

The Vaccine Development Evaluation Centre (VDEC) at Porton Down in Wiltshire facilitates the development and evaluation of new vaccines and therapeutics.

From:
UK Health Security Agency
Published
7 August 2023
Last updated
11 October 2024 — See all updates

Work with VDEC

We work with industry, academia and government. Contact UKHSA today to see how we can help you.

Get in touch

What VDEC does

The Vaccine Development Evaluation Centre (VDEC) provides high-quality, cutting-edge science, building on over 100 years of innovative scientific research. Working with partners, VDEC’s skills and resources enable the development of the vaccines we urgently need to save lives and mitigate the harm from vaccine-preventable disease.

We are actively seeking national and international collaborations and partnerships from all sectors.

VDEC factsheet

What is VDEC

PDF, 894 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

De-risk your product pipeline

VDEC’s high containment biosecure laboratory capabilities (biosafety level (BSL) 2, 3 and 4), are the most extensive of their kind in the UK. They provide a focal point for accelerating the development of:

  • pre-clinical models
  • in vitro assays
  • countermeasures for pathogens of pandemic potential, high-consequence infectious diseases and high-risk infectious diseases

Scientists working in a Class III secure microbiological safety cabinet

What we offer

We offer access to the expertise of over 200 highly trained scientists who run approximately 100 projects per year in 2 state-of-the-art laboratories. We work across the vaccine and therapeutic lifecycle from discovery through clinical testing to post-licensure, all to the appropriate quality standards.

We can support you through:

  1. Discovery and surveillance

  2. Antimicrobial resistance (AMR)

  3. Pre-clinical

  4. Clinical

  5. Post-licensure

  6. Novel and dangerous pathogen training

Case studies

Partnerships and projects

We work closely with international partners and a range of academic bodies.

Find out more about partnerships and collaborations on vaccine development and evaluation

See our work

Over 150,000 mpox vaccines ordered as UK anticipates new strain of virus

Huge vaccine centre launched to bolster UK’s pandemic preparedness

Chief Executive Dr Jenny Harries unveils our latest research facility, the Robinson Building

Updates to this page

Published 7 August 2023
Last updated 11 October 2024 + show all updates

  1. Added the 'organ on a chip' case study.

  2. Added the "Over 150,000 mpox vaccines ordered as UK anticipates new strain of virus" video.

  3. Added novel and dangerous pathogen training link.

  4. Added the VDEC form link.

  5. Updated the content to focus on commercial offering and partnerships.

  6. Added information on clinical and pre-clinical evaluation, and antimicrobial resistance.

  7. Updated to reflect VDEC becoming operational.

  8. First published.

Sign up for emails or print this page

Contents

Related content